At the early stage of development of chemiluminescence in China, many manufacturers have gone through a road of breakthrough of unique items in the market, and of course, the expansion of some items has also provided important value to clinical practice.

If Chinese chemiluminescence would eventually replace imported products completely, it must ensure the accuracy and reliability of the test results. In addition to the improvement of equipment system and methodology, the accuracy of results will involve two very core competitions in the future.

Immunoassay is the largest subdivision in in vitro diagnosis and is in rapid develop-ment, in which chemiluminescence has gradually replaced enzyme-linked immuno-sorbent assay as the mainstream immune diagnosis in China.

China's medical device industry has grown at a compound annual growth rate of 10.54% over the past five years and has become the second largest market in the world.

The total number of first-time registrations of Class II and III medical devices in 2023 was 14,942, a decrease of 129 registrations compared with that of 2022.

Chemiluminescence immunoassay reagent has become the mainstream product in the field of immunoassay and is widely used in clinical in vitro diagnosis due to its advantages such as high sensitivity, good specificity, a wide range of measurements, high degree of supporting automation, and excellent precision and accuracy.

A total of 13 departments, including the National Health Commission (NHC) and the National Development and Reform Commission (NDRC) have jointly formulated an action-implementation plan for cancer prevention and control from 2023 to 2030.

Broncus has entered an equity transfer agreement to acquire a 100% equity interest in Chinese device company Hangzhou Jingliang.

Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture agreement (the "JV Agreement") with leading Chinese medical diagnostic company, Sansure Biotech Inc. ("Sansure"), through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. (the "Sansure Fund"). Sansure Fund is an investment fund formed by Sansure, Changsha Sanway Spring Venture Capital CO., Ltd. ("Sanway Spring") and certain other investors. The JV Agreement was signed on October 27, 2023.

As of 31 October 2023, over 50 Chinese IVD listed companies have announced their Q3 financial results.